{"id":"https://openalex.org/W2120822073","doi":"https://doi.org/10.1586/14737140.2.3.261","title":"Troxacitabine-based therapy of refractory leukemia","display_name":"Troxacitabine-based therapy of refractory leukemia","publication_year":2002,"publication_date":"2002-06-01","ids":{"openalex":"https://openalex.org/W2120822073","doi":"https://doi.org/10.1586/14737140.2.3.261","mag":"2120822073","pmid":"https://pubmed.ncbi.nlm.nih.gov/12113049"},"language":"en","primary_location":{"id":"doi:10.1586/14737140.2.3.261","doi":"https://doi.org/10.1586/14737140.2.3.261","is_oa":false,"landing_page_url":"https://doi.org/10.1586/14737140.2.3.261","pdf_url":null,"source":{"id":"https://openalex.org/S93370067","display_name":"Expert Review of Anticancer Therapy","issn_l":"1473-7140","issn":["1473-7140","1744-8328"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Review of Anticancer Therapy","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5061285204","display_name":"Francis Joseph Giles","orcid":"https://orcid.org/0000-0002-6919-0231","observed_orcids":["https://orcid.org/0000-0002-6919-0231"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Francis J Giles","raw_affiliation_strings":["Section of Developmental Thereputics, The University of Texas M.D. Anderson Cancer Center, Department of Lukemia, 1515 Holcombe Boulevard, Box 428, Houston, TX 77030-4095, USA. fgiles@mdanderson.org"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Section of Developmental Thereputics, The University of Texas M.D. Anderson Cancer Center, Department of Lukemia, 1515 Holcombe Boulevard, Box 428, Houston, TX 77030-4095, USA. fgiles@mdanderson.org","institution_ids":["https://openalex.org/I1343551460"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5061285204"],"corresponding_institution_ids":["https://openalex.org/I1343551460"],"apc_list":null,"apc_paid":null,"fwci":1.0746,"has_fulltext":false,"cited_by_count":14,"citation_normalized_percentile":{"value":0.78358267,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":94},"biblio":{"volume":"2","issue":"3","first_page":"261","last_page":"266"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9937000274658203,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9937000274658203,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11559","display_name":"Retinoids in leukemia and cellular processes","score":0.001500000013038516,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0006000000284984708,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/troxacitabine","display_name":"troxacitabine","score":1.0},{"id":"https://openalex.org/keywords/refractory-leukemia","display_name":"refractory leukemia","score":0.796999990940094},{"id":"https://openalex.org/keywords/acute-myeloid-leukemia","display_name":"acute myeloid leukemia","score":0.9789999723434448},{"id":"https://openalex.org/keywords/chronic-myeloid-leukemia","display_name":"chronic myeloid leukemia","score":0.9670000076293945},{"id":"https://openalex.org/keywords/nucleoside-analogue-resistance","display_name":"nucleoside analogue resistance","score":0.7929999828338623},{"id":"https://openalex.org/keywords/combination-chemotherapy","display_name":"combination chemotherapy","score":0.6850000023841858},{"id":"https://openalex.org/keywords/cytarabine","display_name":"cytarabine","score":0.7369999885559082},{"id":"https://openalex.org/keywords/fludarabine","display_name":"fludarabine","score":0.890999972820282},{"id":"https://openalex.org/keywords/mucositis","display_name":"mucositis","score":0.906000018119812},{"id":"https://openalex.org/keywords/hand-foot-syndrome","display_name":"hand-foot syndrome","score":0.9729999899864197},{"id":"https://openalex.org/keywords/lymphoproliferative-disorders","display_name":"lymphoproliferative disorders","score":0.8550000190734863},{"id":"https://openalex.org/keywords/hematologic-malignancies","display_name":"hematologic malignancies","score":0.7789999842643738}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8429383039474487},{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.7460376024246216},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.691871166229248},{"id":"https://openalex.org/C2779117419","wikidata":"https://www.wikidata.org/wiki/Q1063862","display_name":"Idarubicin","level":4,"score":0.6625035405158997},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.5374010801315308},{"id":"https://openalex.org/C2778041864","wikidata":"https://www.wikidata.org/wiki/Q180983","display_name":"Cytarabine","level":3,"score":0.5012021064758301},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4837070107460022},{"id":"https://openalex.org/C2779263901","wikidata":"https://www.wikidata.org/wiki/Q185916","display_name":"Fludarabine","level":4,"score":0.48145169019699097},{"id":"https://openalex.org/C2778496288","wikidata":"https://www.wikidata.org/wiki/Q6931269","display_name":"Mucositis","level":3,"score":0.4486892819404602},{"id":"https://openalex.org/C2776863199","wikidata":"https://www.wikidata.org/wiki/Q976388","display_name":"Acute leukemia","level":3,"score":0.4447828531265259},{"id":"https://openalex.org/C2780923524","wikidata":"https://www.wikidata.org/wiki/Q239426","display_name":"Mitoxantrone","level":3,"score":0.42733675241470337},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.35933825373649597},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.25750553607940674},{"id":"https://openalex.org/C2776755627","wikidata":"https://www.wikidata.org/wiki/Q408524","display_name":"Cyclophosphamide","level":3,"score":0.08565780520439148},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.06591805815696716},{"id":"https://openalex.org/C87355193","wikidata":"https://www.wikidata.org/wiki/Q411","display_name":"Astrobiology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D003561","descriptor_name":"Cytarabine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D003596","descriptor_name":"Cytosine","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D003596","descriptor_name":"Cytosine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D004148","descriptor_name":"Dioxolanes","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007938","descriptor_name":"Leukemia","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D012074","descriptor_name":"Remission Induction","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015255","descriptor_name":"Idarubicin","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D017321","descriptor_name":"Clinical Trials, Phase I as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017322","descriptor_name":"Clinical Trials, Phase II as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019772","descriptor_name":"Topotecan","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1586/14737140.2.3.261","doi":"https://doi.org/10.1586/14737140.2.3.261","is_oa":false,"landing_page_url":"https://doi.org/10.1586/14737140.2.3.261","pdf_url":null,"source":{"id":"https://openalex.org/S93370067","display_name":"Expert Review of Anticancer Therapy","issn_l":"1473-7140","issn":["1473-7140","1744-8328"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Review of Anticancer Therapy","raw_type":"journal-article"},{"id":"pmid:12113049","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/12113049","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert review of anticancer therapy","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.98580002784729,"id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[{"display_name":"Good health and well-being","score":0.8299999833106995,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":26,"referenced_works":["https://openalex.org/W16058864","https://openalex.org/W1545822988","https://openalex.org/W1558518646","https://openalex.org/W1562405218","https://openalex.org/W1571638899","https://openalex.org/W1596537940","https://openalex.org/W1926050718","https://openalex.org/W1936026926","https://openalex.org/W1939358691","https://openalex.org/W1967157358","https://openalex.org/W1976862545","https://openalex.org/W1985052461","https://openalex.org/W1996376265","https://openalex.org/W2001967406","https://openalex.org/W2024382021","https://openalex.org/W2049310237","https://openalex.org/W2054856869","https://openalex.org/W2073746430","https://openalex.org/W2079966120","https://openalex.org/W2097111310","https://openalex.org/W2109154392","https://openalex.org/W2115633225","https://openalex.org/W2139407325","https://openalex.org/W2169884507","https://openalex.org/W2333633096","https://openalex.org/W2412174789"],"related_works":["https://openalex.org/W2169884507","https://openalex.org/W1939358691","https://openalex.org/W2037428522","https://openalex.org/W2069097994","https://openalex.org/W2148699594","https://openalex.org/W2042633663","https://openalex.org/W2603159220","https://openalex.org/W2043591201","https://openalex.org/W2590617791","https://openalex.org/W2155775840"],"abstract_inverted_index":{"Unique":[0],"among":[1],"currently":[2],"approved":[3],"or":[4],"in-development":[5],"nucleoside":[6],"analogs,":[7],"troxacitabine":[8,92],"(Troxatyl)":[9],"is":[10],"an":[11],"L-nucleoside":[12],"with":[13,50,64,93,102,113,125],"significant":[14],"cytotoxic":[15],"activity.":[16],"Its":[17],"stereochemistry":[18],"and":[19,38,45,55,96],"cellular":[20],"transport":[21],"characteristics":[22],"render":[23],"it":[24],"insensitive":[25],"to":[26,33],"some":[27],"tumor":[28],"cell":[29],"mechanisms":[30],"of":[31,79,91],"resistance":[32],"D-nucleosides,":[34],"such":[35],"as":[36],"cytarabine":[37],"fludarabine.":[39],"Troxacitabine's":[40],"dose-limiting":[41],"toxicities":[42],"were":[43,59],"mucositis":[44],"hand-foot":[46],"syndrome":[47],"in":[48,61,76,100,111,123],"patients":[49,63,101,112,124],"refractory":[51,65,103,114],"leukemia.":[52],"Three":[53],"complete":[54],"one":[56],"partial":[57],"remissions":[58],"observed":[60],"30":[62],"acute":[66,104],"myeloid":[67,81,105],"leukemia":[68,82,106],"on":[69,85],"a":[70,86],"Phase":[71,87,108],"I":[72],"study.":[73,89],"Significant":[74],"activity":[75],"blastic":[77],"phase":[78],"chronic":[80],"was":[83],"seen":[84],"II":[88,109],"Combinations":[90],"ara-C,":[94],"topotecan":[95],"idarubicin":[97],"are":[98,117],"active":[99],"(AML).":[107],"studies":[110],"lymphoproliferative":[115],"diseases":[116],"ongoing.":[118],"Troxacitabine":[119],"merits":[120],"further":[121],"study":[122],"hematological":[126],"malignancies.":[127]},"counts_by_year":[{"year":2020,"cited_by_count":1},{"year":2016,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}